ClinicalTrials.gg
CompletedNCT05842967MONETUpdated Aug 8, 2025Results posted

A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease

A Phase 3 interventional study of RSVpreF and Placebo in RESPIRATORY SYNCYTIAL VIRUS (RSV), sponsored by Pfizer. Completed at 36 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-08.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
885
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to learn about the safety and immunogenicity of a study vaccine (called RSVpreF) in several adult groups. Respiratory Syncytial Virus (RSV) is a common type of virus (germ) that can cause severe illness, where medical help is needed. RSV can lead to airway diseases in all ages. Vaccines help your body make antibodies which help fight against diseases. This is called an immune response. This study will measure how much antibody participants make after receiving RSVpreF (immunogenicity).

The study consists of 2 groups (Substudy A and Substudy B).

Substudy A is seeking approximately 675 participants who are:

  • Between 18 and 60 years of age.
  • Considered having a high likelihood of severe RSV disease due to certain long-term medical conditions. Such medical conditions do not include immunocompromising conditions.

Participants will need to come to the study clinic at least 2 times. At the first clinic visit, participants will receive 1 shot of RSVpreF or placebo in the arm by chance. A placebo looks like the study vaccine but contains no active ingredients. At each clinic visit, a blood sample will be taken. A third (final) visit can be either completed in clinic or via telephone contact. This study is about 6 months long for each participant.

Substudy B is seeking approximately 200 participants who are:

  • At least 18 years of age. About half of the participants will be at least 60 years of age.
  • Considered having a weakened immune system (immunocompromised). Participants will need to come to the study clinic at least 3 times. All participants will receive a shot of RSVpreF at the first study clinic visit. The second study clinic visit will be 1 month later. All participants will receive a second shot of the study vaccine at this second study clinic visit. Blood samples will be taken at the 3 study clinic visits. A fourth (final) visit can be either completed in clinic or via telephone contact. This study is about 7 months long for each participant.
Read the detailed description

This is a Phase 3 protocol that will assess the safety, tolerability, and immunogenicity of Pfizer's RSVpreF in adults at high risk of severe RSV disease. Each substudy design is detailed separately, and these substudies may be conducted in parallel, as required by the clinical plan, within the framework of this protocol.

Substudy A Design:

This is a Phase 3, multicenter, randomized, double-blinded, placebo-controlled study that will assess the safety, tolerability, and immunogenicity of Pfizer's RSVpreF in adults 18 to \<60 years of age considered to be at high risk of RSV disease due to certain chronic medical conditions.

Approximately 675 participants ≥18 to \<60 years of age considered at high risk of RSV disease due to certain chronic medical conditions, excluding immunocompromising conditions, will be randomized to receive a single 120-µg dose of RSVpreF or placebo in a 2:1 ratio. Enrollment will be monitored to help ensure distribution of vaccination across the age range. The duration of study participation for each participant will be 6 months, with 3 scheduled visits.

All participants will have blood drawn at baseline prior to vaccination and at 1 month after vaccination to assess immunogenicity. Immunogenicity elicited at 1 month after vaccination with RSVpreF in Substudy A will be bridged to the immunogenicity of participants 60 years of age and older in the C3671013 study, in which RSVpreF efficacy was demonstrated.

Local reaction and systemic event data will be collected in an e-diary for 7 days after study vaccination (Days 1 through 7, where Day 1 is the day of vaccination). Reported Grade 3 reactogenicity will be assessed by the study site to determine if an unscheduled visit is required.

For all participants, AEs will be collected from informed consent through 1 month following study intervention administration, and AESIs, NDCMCs and SAEs will be collected from informed consent throughout study participation. In addition, AEs occurring up to 48 hours after blood draws that are related to study procedures will be collected.

Substudy B Design:

This is a Phase 3, single-arm, open-label, multicenter study that will assess the safety, tolerability, and immunogenicity of Pfizer's RSVpreF in immunocompromised adults.

Substudy B included approximately 200 immunocompromised adults ≥18 years of age, that will receive 2 120-µg doses of RSVpreF with an interval of 1 month. Approximately 100 participants will be ≥60 years of age and approximately 100 participants will be ≥18 to 60 years of age. Enrollment will be monitored to help ensure distribution of vaccination across the age ranges and underlying immunocompromising conditions. The duration of study participation for each participant will be 7 months, with 4 scheduled visits. All participants will have blood drawn at baseline prior to vaccination and at 1 month after (each) vaccination to assess immunogenicity.

Local reaction and systemic event data will be collected in an e-diary for 7 days after study vaccination (Days 1 through 7, where Day 1 is the day of vaccination). Reported Grade 3 reactogenicity will be assessed by the study site to determine if an unscheduled visit is required.

For all participants, AEs will be collected from informed consent through 1 month following the last study intervention administration, and AESIs, NDCMCs and SAEs will be collected from informed consent throughout study participation. In addition, AEs occurring up to 48 hours after blood draws that are related to study procedures will be collected.

02

Conditions studied

  • RESPIRATORY SYNCYTIAL VIRUS (RSV)

Keywords

  • RESPIRATORY SYNCYTIAL VIRUS (RSV)
  • ADULTS AT HIGH RISK
  • IMMUNOCOMPROMISED ADULTS
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Substudy A Inclusion Criteria:

  1. Capable of giving signed as described per protocol.
  2. Participants ≥18 to \<60 years of age at study enrollment.
  3. ≥12 months (365 days) in the opinion of the investigator at enrollment.
  4. Participants who are willing and able to comply with all scheduled visits, vaccination plan, lifestyle considerations, and other study procedures.
  5. Participants who are considered at high risk of RSV disease by virtue of the following:

    • Adults with chronic pulmonary (including asthma), cardiovascular (excluding isolated hypertension), renal, hepatic, neurologic, hematologic, or metabolic disorders (including diabetes mellitus).

Chronic medical conditions for this substudy are defined as:

- Duration greater than 6 months.

  • Stable disease not requiring a significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of study intervention.
  • Requires regular medical follow-up or ongoing medication or hospitalization in the previous year.

    • Additional groups at high risk include:
  • Residents of nursing homes and other long-term care facilities.

Substudy A Exclusion Criteria:

  1. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  2. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine.
  3. Participants who do not have adequate deltoid muscle mass to allow intramuscular vaccination, in the opinion of the investigator.
  4. Serious chronic disorder, including , end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study.
  5. individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
  6. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

    Note: Specific criteria for participants with known stable infection with can be found in protocol.

  7. Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, immunosuppressive monoclonal antibodies, systemic *, eg, for cancer or an disease, or radiotherapy, from 60 days before study intervention administration or planned receipt throughout the study.

    *Applies to systemic corticosteroids administered for ≥14 days at a dose of ≥20 mg/day of prednisone or equivalent (eg, for cancer or an autoimmune disease). Systemic corticosteroids administered at a dose of \<20 mg/day of prednisone or equivalent are permitted. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin, eyes, or ears) corticosteroids are permitted.

  8. Receipt of blood/plasma products or immunoglobulin within 60 days before study intervention administration or planned receipt of these medications prior to the final blood draw.

    Note: Monoclonal antibodies with targeted mechanisms of action used in the management of chronic illnesses (eg, migraine headaches, osteoporosis) are permitted, provided they do not meet exclusion criterion 7.

  9. Previous vaccination with any licensed or RSV vaccine or planned receipt during study participation.
  10. Participation in other studies involving an investigational product within 28 days prior to consent and/or through and including the 6-month follow-up visit.
  11. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.

Substudy B Inclusion Criteria

  1. Capable of giving signed informed consent as described per protocol.
  2. Participants ≥18 years of age at study enrollment.
  3. Life expectancy ≥12 months (365 days) in the opinion of the investigator at enrollment.
  4. Participants who are willing and able to comply with all scheduled visits, vaccination plan, lifestyle considerations, and other study procedures.
  5. Participants who are immunocompromised by virtue of the following:

    •Having known advanced NSCLC with at least 1 of the following:

    • Has received initial or maintenance chemotherapy at least 2 weeks (14 days) before enrollment (or is treatment-naïve), and is not expected to receive chemotherapy within at least 2 weeks (14 days) after dose administration of initial vaccination or second vaccination; and/or
    • Is receiving treatment (PD-1/PD-L1 inhibitor, CTLA-4 inhibitor) and has undergone at least 1 treatment cycle prior to enrollment; or
    • Is receiving targeted drug therapy (EGFR, ALK, ROS1, BRAF, RET, MET, NTRK inhibitors) and has undergone at least 1 treatment cycle prior to enrollment.

    OR - Is currently undergoing maintenance hemodialysis treatment secondary to end-stage renal disease . OR - Is on active immunomodulator therapy (eg, TNFα inhibitor, tofacitinib, or MTX) for an autoimmune inflammatory disorder (eg, inflammatory arthritis, such as rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis, or inflammatory bowel disease, such as ulcerative colitis or Crohn's disease) at a stable*dose.

    *Stable dose is defined as receiving the same dose for at least 3 months (84 days) with no changes in the 28 days prior to enrollment. See protocol for details on stable dose for MTX.

    OR - Is receiving an SOT (kidney, liver, lung, or heart) at least 3 months (84 days) prior to enrollment (Visit 201) and with no acute rejection episodes within 2 months (60 days) prior to enrollment (Visit 201).

    Substudy B Exclusion Criteria:

1.Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.

2.History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine.

3.Participants with a history of transplant rejection, or PTLD, or participants who have had treatment for these conditions within 3 months (84 days) prior to study enrollment.

4.Participants who do not have adequate deltoid muscle mass to allow intramuscular vaccination, in the opinion of the investigator.

5.Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

Note: Specific criteria for participants with known stable infection with HIV can be found in protocol.

6.Receipt of investigational or approved monoclonal antibodies against RSV within 6 months before study intervention administration.

7.Receipt of blood/plasma products or immunoglobulin (IVIG, SCIG) within 60 days before study intervention administration or planned receipt of these medications prior to the final blood draw.

Note: Please see the inclusion criteria in the protocol regarding criteria for targeted immunoglobulin therapies for underlying medical conditions.

Note: Monoclonal antibodies with targeted mechanisms of action used in the management of chronic illnesses (eg, migraine headaches, osteoporosis) are permitted.

8.Previous vaccination with any licensed or investigational RSV vaccine or planned receipt during study participation.

9.Participation in other studies involving an investigational product within 28 days prior to consent and/or through and including the 6-month follow-up visit.

10.Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
885 participants (actual)

Study arms

  • Experimental
    Substudy A - RSVpreF

    Participants will receive a single 120-µg dose of RSVpreF at Visit 1

    Biological: RSVpreF

  • Placebo comparator
    Substudy A - Placebo

    Participants will receive placebo at Visit 1

    Other: Placebo

  • Experimental
    Substudy B - RSVpreF

    Participants will receive 120-µg doses of RSVpreF at Visit 1 and Visit 2 (open label, single arm only)

    Biological: RSVpreF

Interventions

  • BiologicalRSVpreF

    120-µg

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. SSA: Percentage of Participants With Local Reactions Within 7 Days After Vaccination

    Local reactions included pain at injection site, redness and swelling, recorded by participants in an electronic diary (e-diary). Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity and severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild: \>2.5 cm to 5.0 cm; moderate: \>5.0 cm to 10.0 cm; severe: \>10 cm.

    Time frame: Within 7 Days after Vaccination (Vaccination on Day 1)

  2. SSA: Percentage of Participants With Systemic Events Within 7 Days After Vaccination

    Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain and joint pain. These were recorded by participants in an e-diary. Fever defined as oral temperature \>=38.0 degrees Celsius (deg C) and categorized as mild: \>=38.0 to 38.4 deg C, moderate: \>38.4 to 38.9 deg C and severe: \>38.9 to 40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, nausea, muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity.

    Time frame: Within 7 Days after Vaccination (Vaccination on Day 1)

  3. SSA: Percentage of Participants With Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination

    An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were included. AEs included both serious and all non-serious adverse events.

    Time frame: Within 1 Month after Vaccination (Vaccination on Day 1)

  4. SSA: Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Vaccination Throughout the Study

    A NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Newly diagnosed chronic medical condition did not include illnesses considered to be temporary conditions.

    Time frame: Within 6 Months after Vaccination (Vaccination on Day 1)

  5. SSA: Percentage of Participants With Serious Adverse Events (SAEs) Throughout the Study

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic and other important medical event were included in this outcome measure.

    Time frame: Within 6 Months after Vaccination (Vaccination on Day 1)

  6. SSA: Geometric Mean Ratio (GMR) Estimated by Ratio of the Geometric Mean Titers (GMTs) at 1 Month After Vaccination in Study C3671023 Participants Compared to Study C3671013 Adults >= 60 Years

    In this outcome measure, GMTs for RSV A and RSV B neutralizing titers (NTs) are reported. In statistical section, GMT ratio estimated by the ratio of the GMTs for RSV A and RSV B serum NTs at 1 month after vaccination with RSVpreF in current study C3671023 participants to that in study C3671013 adults \>=60 years of age, is reported. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student t distribution).

    Time frame: At 1 Month after Vaccination (Vaccination on Day 1)

  7. SSA: Percentage of Participants With Seroresponse Rate and Difference in Seroresponse Rates of RSV A and RSV B Serum NTs at 1 Month After Vaccination for Participants in Study C3671023 and C3671013 Adults >= 60 Years

    Seroresponse was defined as achieving a \>=4-fold rise from baseline (before vaccination), if the baseline measurement was above the lower limit of quantitation (LLOQ). If the baseline measurement was below the LLOQ, a postvaccination assay result \>=4\* LLOQ was considered a seroresponse.

    Time frame: At 1 Month after Vaccination (Vaccination on Day 1)

  8. SSB: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1

    Local reactions included pain at injection site, redness and swelling, recorded by participants in an e-diary. Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity and severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit=0.5 cm. Redness and swelling were graded as mild: \> 2.0 cm to 5.0 cm; moderate: \> 5.0 cm to 10.0 cm and severe: \> 10 cm.

    Time frame: Within 7 Days after Vaccination 1 (Vaccination 1 on Day 1)

  9. SSB: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2

    Local reactions included pain at injection site, redness and swelling, recorded by participants in an e-diary. Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity and severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit = 0.5 cm. Redness and swelling were graded as mild: \>2.0 cm to 5.0 cm; moderate: \>5.0 cm to 10.0 cm and severe: \>10 cm.

    Time frame: Within 7 Days after Vaccination 2 (Vaccination 2: 1-month post-vaccination 1 on Day 1)

  10. SSB: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1

    Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain and joint pain. These were recorded by participants in an e-diary. Fever defined as oral temperature \>=38.0 degrees Celsius (deg C) and categorized as mild: \>=38.0 to 38.4 deg C, moderate: \>38.4 to 38.9 deg C and severe: \>38.9 to 40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, nausea, muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity.

    Time frame: Within 7 Days after Vaccination 1 (Vaccination 1 on Day 1)

  11. SSB: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2

    Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain and joint pain. These were recorded by participants in an e-diary. Fever defined as oral temperature \>=38.0 degrees Celsius (deg C) and categorized as mild: \>=38.0 to 38.4 deg C, moderate: \>38.4 to 38.9 deg C and severe: \>38.9 to 40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, nausea, muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity.

    Time frame: Within 7 Days after Vaccination 2 (Vaccination 2: 1-month post-vaccination 1 on Day 1)

  12. SSB: Percentage of Participants With AEs From Vaccination 1 Through 1 Month After Vaccination 2

    An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were included. AEs included both serious and all non-serious adverse events.

    Time frame: From Vaccination 1 (on Day 1) through 1 month after Vaccination 2 (1 month after Vaccination 1) [approximately up to maximum of 2 months]

  13. SSB: Percentage of Participants With NDCMCs From Vaccination Throughout the Study

    A NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Newly diagnosed chronic medical condition did not include illnesses considered to be temporary conditions.

    Time frame: From Vaccination 1 (on Day 1) through 6 months after Vaccination 2 (1 month after Vaccination 1) [approximately up to maximum of 7 months]

  14. SSB: Percentage of Participants With SAEs Throughout the Study

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic and other important medical event were included in this outcome measure.

    Time frame: From Vaccination 1 (on Day 1) through 6 months after Vaccination 2 (1 month after Vaccination 1) [approximately up to maximum of 7 months]

  15. SSB: GMT of NT for RSV A and RSV B Before Vaccination 1

    GMT of RSV A and RSV B before vaccination were reported in this outcome measure. Assay results below the lower limit of quantification (LLOQ) were set to 0.5\*LLOQ. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).

    Time frame: Before Vaccination 1 (on Day 1)

  16. SSB: GMT of NT for RSV A and RSV B 1 Month After Vaccination 1

    GMT of RSV A and RSV B before vaccination were reported in this outcome measure. Assay results below the lower limit of quantification (LLOQ) were set to 0.5\*LLOQ. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).

    Time frame: 1 Month After Vaccination 1 (on Day 1)

  17. SSB: GMT of NT for RSV A and RSV B 1 Month After Vaccination 2

    GMT of RSV A and RSV B before vaccination were reported in this outcome measure. Assay results below the lower limit of quantification (LLOQ) were set to 0.5\*LLOQ. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).

    Time frame: 1 Month After Vaccination 2 (1-month post Vaccination 1)

Secondary outcomes

  1. SSB: Geometric Mean Fold Rise (GMFR) of NTs for RSV A and RSV B From Vaccination 1 to 1 Month Post-Vaccination 1

    GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).

    Time frame: At 1 Month After Vaccination 1 (on Day 1) to 1 Month Post-Vaccination 1

  2. SSB: GMFR of NTs for RSV A and RSV B From Vaccination 1 to 1 Month Post-Vaccination 2

    GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).

    Time frame: At 1 Month After Vaccination 1 (on Day 1) to 1 Month Post-Vaccination 2

  3. SSA: GMT of NTs for RSV A and RSV B Before Vaccination and 1 Month After Vaccination

    GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).

    Time frame: SSA: Before Vaccination (on Day 1) and 1 Month After Vaccination

  4. SSA: GMFR of NTs for RSV A and RSV B From Before Vaccination to 1 Month After Vaccination

    GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).

    Time frame: SSA: Before Vaccination (on Day 1) and 1 Month After Vaccination

07

Results

Posted Aug 8, 2025

Participant flow

Substudy A (SSA) and substudy B (SSB) are reported differently. SSA was randomized; SSB was open-label single-arm. Enrollment number 885 derived from participants with IP assigned in SSA (681 randomized) and SSB (204). Since no randomization in SSB (single arm), tables of SSB present 217 participants as starting substudy (signed informed consent), out of which 203 vaccinated. In SSA: 678 vaccinated.

Period 1: SSA
Participant flow — Period 1: SSA
MilestoneSSA: RSVpreFSSA: PlaceboSSB: RSVpreF, >= 18 to < 60 YearsSSB: RSVpreF, >= 60 Years
Started45422700
Vaccinated45322500
Completed43221800
Not completed22900
Withdrew: Adverse event1100
Withdrew: Death1000
Withdrew: Lost to follow-up16400
Withdrew: Physician decision1000
Withdrew: Withdrawal by subject2200
Withdrew: Randomized but not vaccinated1200
Period 2: SSB
Participant flow — Period 2: SSB
MilestoneSSA: RSVpreFSSA: PlaceboSSB: RSVpreF, >= 18 to < 60 YearsSSB: RSVpreF, >= 60 Years
Started00101116
Vaccinated0096107
Completed0089103
Not completed001213
Withdrew: Adverse event0020
Withdrew: Lost to follow-up0043
Withdrew: Withdrawal by subject0010
Withdrew: Enrolled but not vaccinated0059
Withdrew: Protocol violation0001

Outcome measures

PrimarySSA: Percentage of Participants With Local Reactions Within 7 Days After Vaccination

Local reactions included pain at injection site, redness and swelling, recorded by participants in an electronic diary (e-diary). Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity and severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild: \>2.5 cm to 5.0 cm; moderate: \>5.0 cm to 10.0 cm; severe: \>10 cm.

Time frame:
Within 7 Days after Vaccination (Vaccination on Day 1)
Reported as:
Number · Percentage of Participants
SSA: Percentage of Participants With Local Reactions Within 7 Days After Vaccination
Percentage of ParticipantsSSA: RSVpreFSSA: Placebo
Pain at injection site: Mild29.7 (25.5 to 34.2)10.2 (6.6 to 14.9)
Pain at injection site: Moderate5.5 (3.6 to 8.1)0.4 (0.0 to 2.5)
Pain at injection site: Severe0 (0.0 to 0.8)0 (0.0 to 1.6)
Redness: Mild3.8 (2.2 to 6.0)0 (0.0 to 1.6)
Redness: Moderate2.2 (1.1 to 4.0)0.4 (0.0 to 2.5)
Redness: Severe0 (0.0 to 0.8)0 (0.0 to 1.6)
Swelling: Mild4.0 (2.4 to 6.2)0.4 (0.0 to 2.5)
Swelling: Moderate2.9 (1.5 to 4.9)0.4 (0.0 to 2.5)
Swelling: Severe0.2 (0.0 to 1.2)0 (0.0 to 1.6)
PrimarySSA: Percentage of Participants With Systemic Events Within 7 Days After Vaccination

Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain and joint pain. These were recorded by participants in an e-diary. Fever defined as oral temperature \>=38.0 degrees Celsius (deg C) and categorized as mild: \>=38.0 to 38.4 deg C, moderate: \>38.4 to 38.9 deg C and severe: \>38.9 to 40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, nausea, muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity.

Time frame:
Within 7 Days after Vaccination (Vaccination on Day 1)
Reported as:
Number · Percentage of participants
SSA: Percentage of Participants With Systemic Events Within 7 Days After Vaccination
Percentage of participantsSSA: RSVpreFSSA: Placebo
Fever: 38.0°C to 38.4°C0.4 (0.1 to 1.6)0.4 (0.0 to 2.5)
Fever: >38.4°C to 38.9°C1.1 (0.4 to 2.6)0.9 (0.1 to 3.2)
Fever: >38.9°C to 40.0°C0 (0.0 to 0.8)0 (0.0 to 1.6)
Fatigue: Mild18.2 (14.7 to 22.1)22.2 (17.0 to 28.2)
Fatigue: Moderate18.2 (14.7 to 22.1)15.6 (11.1 to 21.0)
Fatigue: Severe0.9 (0.2 to 2.3)0.4 (0.0 to 2.5)
Headache: Mild20.8 (17.2 to 24.9)18.7 (13.8 to 24.4)
Headache: Moderate7.3 (5.1 to 10.1)11.6 (7.7 to 16.5)
Headache: Severe0.2 (0.0 to 1.2)0 (0.0 to 1.6)
Muscle Pain: Mild15.7 (12.5 to 19.4)9.8 (6.2 to 14.4)
Muscle Pain: Moderate8.6 (6.2 to 11.6)6.2 (3.4 to 10.2)
Muscle Pain: Severe0 (0.0 to 0.8)0 (0.0 to 1.6)
Joint Pain: Mild7.1 (4.9 to 9.9)4.0 (1.8 to 7.5)
Joint Pain: Moderate5.1 (3.3 to 7.6)6.2 (3.4 to 10.2)
Joint Pain: Severe0.2 (0.0 to 1.2)0 (0.0 to 1.6)
Nausea: Mild9.3 (6.8 to 12.4)8.9 (5.5 to 13.4)
Nausea: Moderate2.4 (1.2 to 4.3)0.9 (0.1 to 3.2)
Nausea: Severe0 (0.0 to 0.8)0.4 (0.0 to 2.5)
Vomiting: Mild1.6 (0.6 to 3.2)0.4 (0.0 to 2.5)
Vomiting: Moderate0.4 (0.1 to 1.6)0.9 (0.1 to 3.2)
Vomiting: Severe0 (0.0 to 0.8)0 (0.0 to 1.6)
Diarrhea: Mild11.1 (8.3 to 14.4)12.4 (8.4 to 17.5)
Diarrhea: Moderate3.1 (1.7 to 5.2)3.6 (1.5 to 6.9)
Diarrhea: Severe0.7 (0.1 to 1.9)0.9 (0.1 to 3.2)
PrimarySSA: Percentage of Participants With Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination

An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were included. AEs included both serious and all non-serious adverse events.

Time frame:
Within 1 Month after Vaccination (Vaccination on Day 1)
Reported as:
Number · Percentage of participants
SSA: Percentage of Participants With Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination
Percentage of participantsSSA: RSVpreFSSA: Placebo
SSA: Percentage of Participants With Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination7.1 (4.9 to 9.8)7.6 (4.5 to 11.8)
PrimarySSA: Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Vaccination Throughout the Study

A NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Newly diagnosed chronic medical condition did not include illnesses considered to be temporary conditions.

Time frame:
Within 6 Months after Vaccination (Vaccination on Day 1)
Reported as:
Number · Percentage of participants
SSA: Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Vaccination Throughout the Study
Percentage of participantsSSA: RSVpreFSSA: Placebo
SSA: Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Vaccination Throughout the Study0.7 (0.1 to 1.9)2.2 (0.7 to 5.1)
PrimarySSA: Percentage of Participants With Serious Adverse Events (SAEs) Throughout the Study

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic and other important medical event were included in this outcome measure.

Time frame:
Within 6 Months after Vaccination (Vaccination on Day 1)
Reported as:
Number · Percentage of participants
SSA: Percentage of Participants With Serious Adverse Events (SAEs) Throughout the Study
Percentage of participantsSSA: RSVpreFSSA: Placebo
SSA: Percentage of Participants With Serious Adverse Events (SAEs) Throughout the Study1.1 (0.4 to 2.6)3.1 (1.3 to 6.3)
PrimarySSA: Geometric Mean Ratio (GMR) Estimated by Ratio of the Geometric Mean Titers (GMTs) at 1 Month After Vaccination in Study C3671023 Participants Compared to Study C3671013 Adults >= 60 Years

In this outcome measure, GMTs for RSV A and RSV B neutralizing titers (NTs) are reported. In statistical section, GMT ratio estimated by the ratio of the GMTs for RSV A and RSV B serum NTs at 1 month after vaccination with RSVpreF in current study C3671023 participants to that in study C3671013 adults \>=60 years of age, is reported. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student t distribution).

Time frame:
At 1 Month after Vaccination (Vaccination on Day 1)
Reported as:
Least squares mean · Titer
SSA: Geometric Mean Ratio (GMR) Estimated by Ratio of the Geometric Mean Titers (GMTs) at 1 Month After Vaccination in Study C3671023 Participants Compared to Study C3671013 Adults >= 60 Years
TiterC3671023 SSA: RSVpreFC3671013: RSVpreF, >=60 Years
RSV A41097 (37986.1 to 44463.4)26225 (24143.1 to 28485.7)
RSV B37416 (34277.9 to 40842.0)24680 (22504.3 to 27065.4)
Statistical analysis
  • C3671023 SSA: RSVpreF vs C3671013: RSVpreF, >=60 Years · Gmr: 1.57 · 95% CI 1.396 to 1.759GMRs (ratio of GMTs from C3671023 SSA to C3671013 immunogenicity subset), 2-sided CI were calculated by exponentiating difference in LS means, corresponding CIs based on regression model. Data reported here is for RSV A.
  • C3671023 SSA: RSVpreF vs C3671013: RSVpreF, >=60 Years · Gmr: 1.52 · 95% CI 1.333 to 1.725GMRs (ratio of GMTs from C3671023 SSA to C3671013 immunogenicity subset), 2-sided CI were calculated by exponentiating difference in LS means, corresponding CIs based on regression model. Data reported here is for RSV B.
PrimarySSA: Percentage of Participants With Seroresponse Rate and Difference in Seroresponse Rates of RSV A and RSV B Serum NTs at 1 Month After Vaccination for Participants in Study C3671023 and C3671013 Adults >= 60 Years

Seroresponse was defined as achieving a \>=4-fold rise from baseline (before vaccination), if the baseline measurement was above the lower limit of quantitation (LLOQ). If the baseline measurement was below the LLOQ, a postvaccination assay result \>=4\* LLOQ was considered a seroresponse.

Time frame:
At 1 Month after Vaccination (Vaccination on Day 1)
Reported as:
Number · Percentage of participants
SSA: Percentage of Participants With Seroresponse Rate and Difference in Seroresponse Rates of RSV A and RSV B Serum NTs at 1 Month After Vaccination for Participants in Study C3671023 and C3671013 Adults >= 60 Years
Percentage of participantsC3671023 SSA: RSVpreFC3671013: RSVpreF, >=60 Years
RSV A93.1 (90.3 to 95.3)88.0 (84.4 to 91.0)
RSV B93.4 (90.6 to 95.5)85.0 (81.2 to 88.4)
Statistical analysis
  • C3671023 SSA: RSVpreF vs C3671013: RSVpreF, >=60 Years · Difference in percentage: 5.1 · 95% CI 1.2 to 9.2Difference (C3671023 SSA, compared to C3671013 immunogenicity subset) in proportions, expressed as a percentage; 95% CIs for percentage difference were calculated using exact method based on Miettinen and Nurminen. Data reported here is for RSV A.
  • C3671023 SSA: RSVpreF vs C3671013: RSVpreF, >=60 Years · Difference in percentage: 8.3 · 95% CI 4.2 to 12.6Difference (C3671023 SSA, compared to C3671013 immunogenicity subset) in proportions, expressed as a percentage; 95% CIs for percentage difference were calculated using exact method based on Miettinen and Nurminen. Data reported here is for RSV B.
PrimarySSB: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1

Local reactions included pain at injection site, redness and swelling, recorded by participants in an e-diary. Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity and severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit=0.5 cm. Redness and swelling were graded as mild: \> 2.0 cm to 5.0 cm; moderate: \> 5.0 cm to 10.0 cm and severe: \> 10 cm.

Time frame:
Within 7 Days after Vaccination 1 (Vaccination 1 on Day 1)
Reported as:
Number · Percentage of participants
SSB: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1
Percentage of participantsSSB: RSVpreF, >= 18 to < 60 YearsSSB: RSVpreF, >= 60 Years
Pain at injection site: Mild25.0 (16.7 to 34.9)16.8 (10.3 to 25.3)
Pain at injection site: Moderate1.0 (0.0 to 5.7)0 (0.0 to 3.4)
Pain at injection site: Severe0 (0.0 to 3.8)0 (0.0 to 3.4)
Redness: Mild5.2 (1.7 to 11.7)1.9 (0.2 to 6.6)
Redness: Moderate1.0 (0.0 to 5.7)1.9 (0.2 to 6.6)
Redness: Severe0 (0.0 to 3.8)0 (0.0 to 3.4)
Swelling: Mild6.3 (2.3 to 13.1)0.9 (0.0 to 5.1)
Swelling: Moderate2.1 (0.3 to 7.3)1.9 (0.2 to 6.6)
Swelling: Severe0 (0.0 to 3.8)0 (0.0 to 3.4)
PrimarySSB: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2

Local reactions included pain at injection site, redness and swelling, recorded by participants in an e-diary. Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity and severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit = 0.5 cm. Redness and swelling were graded as mild: \>2.0 cm to 5.0 cm; moderate: \>5.0 cm to 10.0 cm and severe: \>10 cm.

Time frame:
Within 7 Days after Vaccination 2 (Vaccination 2: 1-month post-vaccination 1 on Day 1)
Reported as:
Number · Percentage of participants
SSB: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2
Percentage of participantsSSB: RSVpreF, >= 18 to < 60 YearsSSB: RSVpreF, >= 60 Years
Pain at injection site: Mild42.6 (32.4 to 53.2)29.5 (21.0 to 39.2)
Pain at injection site: Moderate4.3 (1.2 to 10.5)1.9 (0.2 to 6.7)
Pain at injection site: Severe0 (0.0 to 3.8)0 (0.0 to 3.5)
Redness: Mild2.1 (0.3 to 7.5)1.9 (0.2 to 6.7)
Redness: Moderate0 (0.0 to 3.8)1.9 (0.2 to 6.7)
Redness: Severe0 (0.0 to 3.8)0 (0.0 to 3.5)
Swelling: Mild2.1 (0.3 to 7.5)3.8 (1.0 to 9.5)
Swelling: Moderate1.1 (0.0 to 5.8)5.7 (2.1 to 12.0)
Swelling: Severe0 (0.0 to 3.8)0 (0.0 to 3.5)
PrimarySSB: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1

Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain and joint pain. These were recorded by participants in an e-diary. Fever defined as oral temperature \>=38.0 degrees Celsius (deg C) and categorized as mild: \>=38.0 to 38.4 deg C, moderate: \>38.4 to 38.9 deg C and severe: \>38.9 to 40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, nausea, muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity.

Time frame:
Within 7 Days after Vaccination 1 (Vaccination 1 on Day 1)
Reported as:
Number · Percentage of participants
SSB: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1
Percentage of participantsSSB: RSVpreF, >= 18 to < 60 YearsSSB: RSVpreF, >= 60 Years
Fever: 38.0°C to 38.4°C1.0 (0.0 to 5.7)0.9 (0.0 to 5.1)
Fever: >38.4°C to 38.9°C0 (0.0 to 3.8)0 (0.0 to 3.4)
Fever: >38.9°C to 40.0°C0 (0.0 to 3.8)0 (0.0 to 3.4)
Fatigue: Mild20.8 (13.2 to 30.3)19.6 (12.6 to 28.4)
Fatigue: Moderate16.7 (9.8 to 25.6)22.4 (14.9 to 31.5)
Fatigue: Severe2.1 (0.3 to 7.3)2.8 (0.6 to 8.0)
Headache: Mild29.2 (20.3 to 39.3)15.0 (8.8 to 23.1)
Headache: Moderate9.4 (4.4 to 17.1)6.5 (2.7 to 13.0)
Headache: Severe0 (0.0 to 3.8)0.9 (0.0 to 5.1)
Vomiting: Mild4.2 (1.1 to 10.3)0.9 (0.0 to 5.1)
Vomiting: Moderate0 (0.0 to 3.8)0 (0.0 to 3.4)
Vomiting: Severe0 (0.0 to 3.8)0 (0.0 to 3.4)
Nausea: Mild9.4 (4.4 to 17.1)3.7 (1.0 to 9.3)
Nausea: Moderate3.1 (0.6 to 8.9)4.7 (1.5 to 10.6)
Nausea: Severe0 (0.0 to 3.8)0 (0.0 to 3.4)
Diarrhea: Mild15.6 (9.0 to 24.5)12.1 (6.6 to 19.9)
Diarrhea: Moderate6.3 (2.3 to 13.1)5.6 (2.1 to 11.8)
Diarrhea: Severe0 (0.0 to 3.8)0 (0.0 to 3.4)
Muscle Pain: Mild18.8 (11.5 to 28.0)13.1 (7.3 to 21.0)
Muscle Pain: Moderate7.3 (3.0 to 14.4)5.6 (2.1 to 11.8)
Muscle Pain: Severe0 (0.0 to 3.8)1.9 (0.2 to 6.6)
Joint Pain: Mild10.4 (5.1 to 18.3)11.2 (5.9 to 18.8)
Joint Pain: Moderate7.3 (3.0 to 14.4)8.4 (3.9 to 15.4)
Joint Pain: Severe0 (0.0 to 3.8)1.9 (0.2 to 6.6)
PrimarySSB: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2

Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain and joint pain. These were recorded by participants in an e-diary. Fever defined as oral temperature \>=38.0 degrees Celsius (deg C) and categorized as mild: \>=38.0 to 38.4 deg C, moderate: \>38.4 to 38.9 deg C and severe: \>38.9 to 40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, nausea, muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity.

Time frame:
Within 7 Days after Vaccination 2 (Vaccination 2: 1-month post-vaccination 1 on Day 1)
Reported as:
Number · Percentage of participants
SSB: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2
Percentage of participantsSSB: RSVpreF, >= 18 to < 60 YearsSSB: RSVpreF, >= 60 Years
Fever: 38.0°C to 38.4°C0 (0.0 to 3.8)0 (0.0 to 3.5)
Fever: >38.4°C to 38.9°C0 (0.0 to 3.8)0 (0.0 to 3.5)
Fever: >38.9°C to 40.0°C0 (0.0 to 3.8)0 (0.0 to 3.5)
Fatigue: Mild19.1 (11.8 to 28.6)23.8 (16.0 to 33.1)
Fatigue: Moderate18.1 (10.9 to 27.4)19.0 (12.0 to 27.9)
Fatigue: Severe0 (0.0 to 3.8)0 (0.0 to 3.5)
Headache: Mild13.8 (7.6 to 22.5)19.0 (12.0 to 27.9)
Headache: Moderate10.6 (5.2 to 18.7)5.7 (2.1 to 12.0)
Headache: Severe0 (0.0 to 3.8)1.0 (0.0 to 5.2)
Vomiting: Mild2.1 (0.3 to 7.5)1.0 (0.0 to 5.2)
Vomiting: Moderate0 (0.0 to 3.8)0 (0.0 to 3.5)
Vomiting: Severe0 (0.0 to 3.8)0 (0.0 to 3.5)
Nausea: Mild5.3 (1.7 to 12.0)5.7 (2.1 to 12.0)
Nausea: Moderate1.1 (0.0 to 5.8)1.0 (0.0 to 5.2)
Nausea: Severe0 (0.0 to 3.8)0 (0.0 to 3.5)
Diarrhea: Mild6.4 (2.4 to 13.4)10.5 (5.3 to 18.0)
Diarrhea: Moderate5.3 (1.7 to 12.0)2.9 (0.6 to 8.1)
Diarrhea: Severe0 (0.0 to 3.8)0 (0.0 to 3.5)
Muscle Pain: Mild16.0 (9.2 to 25.0)15.2 (9.0 to 23.6)
Muscle Pain: Moderate3.2 (0.7 to 9.0)8.6 (4.0 to 15.6)
Muscle Pain: Severe0 (0.0 to 3.8)0 (0.0 to 3.5)
Joint Pain: Mild8.5 (3.7 to 16.1)12.4 (6.8 to 20.2)
Joint Pain: Moderate3.2 (0.7 to 9.0)4.8 (1.6 to 10.8)
Joint Pain: Severe0 (0.0 to 3.8)0 (0.0 to 3.5)
PrimarySSB: Percentage of Participants With AEs From Vaccination 1 Through 1 Month After Vaccination 2

An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were included. AEs included both serious and all non-serious adverse events.

Time frame:
From Vaccination 1 (on Day 1) through 1 month after Vaccination 2 (1 month after Vaccination 1) [approximately up to maximum of 2 months]
Reported as:
Number · Percentage of participants
SSB: Percentage of Participants With AEs From Vaccination 1 Through 1 Month After Vaccination 2
Percentage of participantsSSB: RSVpreF, >= 18 to < 60 YearsSSB: RSVpreF, >= 60 Years
SSB: Percentage of Participants With AEs From Vaccination 1 Through 1 Month After Vaccination 213.5 (7.4 to 22.0)22.4 (14.9 to 31.5)
PrimarySSB: Percentage of Participants With NDCMCs From Vaccination Throughout the Study

A NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Newly diagnosed chronic medical condition did not include illnesses considered to be temporary conditions.

Time frame:
From Vaccination 1 (on Day 1) through 6 months after Vaccination 2 (1 month after Vaccination 1) [approximately up to maximum of 7 months]
Reported as:
Number · Percentage of participants
SSB: Percentage of Participants With NDCMCs From Vaccination Throughout the Study
Percentage of participantsSSB: RSVpreF, >= 18 to < 60 YearsSSB: RSVpreF, >= 60 Years
SSB: Percentage of Participants With NDCMCs From Vaccination Throughout the Study2.1 (0.3 to 7.3)6.5 (2.7 to 13.0)
PrimarySSB: Percentage of Participants With SAEs Throughout the Study

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic and other important medical event were included in this outcome measure.

Time frame:
From Vaccination 1 (on Day 1) through 6 months after Vaccination 2 (1 month after Vaccination 1) [approximately up to maximum of 7 months]
Reported as:
Number · Percentage of participants
SSB: Percentage of Participants With SAEs Throughout the Study
Percentage of participantsSSB: RSVpreF, >= 18 to < 60 YearsSSB: RSVpreF, >= 60 Years
SSB: Percentage of Participants With SAEs Throughout the Study7.3 (3.0 to 14.4)14.0 (8.1 to 22.1)
PrimarySSB: GMT of NT for RSV A and RSV B Before Vaccination 1

GMT of RSV A and RSV B before vaccination were reported in this outcome measure. Assay results below the lower limit of quantification (LLOQ) were set to 0.5\*LLOQ. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).

Time frame:
Before Vaccination 1 (on Day 1)
Reported as:
Geometric mean · Titer
SSB: GMT of NT for RSV A and RSV B Before Vaccination 1
TiterSSB: RSVpreF, >= 18 to < 60 YearsSSB: RSVpreF, >= 60 Years
RSV A2943 (2417.9 to 3580.9)3289 (2735.1 to 3954.1)
RSV B2584 (2120.6 to 3147.9)2992 (2416.5 to 3704.1)
PrimarySSB: GMT of NT for RSV A and RSV B 1 Month After Vaccination 1

GMT of RSV A and RSV B before vaccination were reported in this outcome measure. Assay results below the lower limit of quantification (LLOQ) were set to 0.5\*LLOQ. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).

Time frame:
1 Month After Vaccination 1 (on Day 1)
Reported as:
Geometric mean · Titer
SSB: GMT of NT for RSV A and RSV B 1 Month After Vaccination 1
TiterSSB: RSVpreF, >= 18 to < 60 YearsSSB: RSVpreF, >= 60 Years
RSV A26173 (19937.1 to 34359.2)26075 (20513.1 to 33144.1)
RSV B24701 (18300.5 to 33340.1)25384 (19749.5 to 32626.2)
PrimarySSB: GMT of NT for RSV A and RSV B 1 Month After Vaccination 2

GMT of RSV A and RSV B before vaccination were reported in this outcome measure. Assay results below the lower limit of quantification (LLOQ) were set to 0.5\*LLOQ. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).

Time frame:
1 Month After Vaccination 2 (1-month post Vaccination 1)
Reported as:
Geometric mean · Titer
SSB: GMT of NT for RSV A and RSV B 1 Month After Vaccination 2
TiterSSB: RSVpreF, >= 18 to < 60 YearsSSB: RSVpreF, >= 60 Years
RSV A21910 (17308.8 to 27733.3)25159 (20085.1 to 31515.2)
RSV B20936 (16154.0 to 27134.4)22774 (18016.7 to 28788.3)
SecondarySSB: Geometric Mean Fold Rise (GMFR) of NTs for RSV A and RSV B From Vaccination 1 to 1 Month Post-Vaccination 1

GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).

Time frame:
At 1 Month After Vaccination 1 (on Day 1) to 1 Month Post-Vaccination 1
Reported as:
Geometric mean · Fold rise
SSB: Geometric Mean Fold Rise (GMFR) of NTs for RSV A and RSV B From Vaccination 1 to 1 Month Post-Vaccination 1
Fold riseSSB: RSVpreF, >= 18 to < 60 YearsSSB: RSVpreF, >= 60 Years
RSV A8.8 (6.76 to 11.53)7.9 (6.21 to 10.13)
RSV B9.6 (7.31 to 12.51)8.5 (6.70 to 10.75)
SecondarySSB: GMFR of NTs for RSV A and RSV B From Vaccination 1 to 1 Month Post-Vaccination 2

GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).

Time frame:
At 1 Month After Vaccination 1 (on Day 1) to 1 Month Post-Vaccination 2
Reported as:
Geometric mean · Fold rise
SSB: GMFR of NTs for RSV A and RSV B From Vaccination 1 to 1 Month Post-Vaccination 2
Fold riseSSB: RSVpreF, >= 18 to < 60 YearsSSB: RSVpreF, >= 60 Years
RSV A7.4 (5.88 to 9.29)7.7 (6.11 to 9.58)
RSV B8.1 (6.45 to 10.18)7.6 (6.06 to 9.57)
SecondarySSA: GMT of NTs for RSV A and RSV B Before Vaccination and 1 Month After Vaccination

GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).

Time frame:
SSA: Before Vaccination (on Day 1) and 1 Month After Vaccination
Reported as:
Geometric mean · Titer
SSA: GMT of NTs for RSV A and RSV B Before Vaccination and 1 Month After Vaccination
TiterSSA: RSVpreFSSA: Placebo
RSV A: Before Vaccination2388 (2207.7 to 2583.3)2797 (2516.8 to 3108.9)
RSV A: 1 month after vaccination41595 (38416.6 to 45037.5)2660 (2395.2 to 2953.9)
RSV B: Before Vaccination2075 (1899.7 to 2265.4)2230 (1988.6 to 2501.6)
RSV B: 1 month after vaccination38450 (35187.5 to 42014.7)2135 (1905.9 to 2391.3)
SecondarySSA: GMFR of NTs for RSV A and RSV B From Before Vaccination to 1 Month After Vaccination

GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).

Time frame:
SSA: Before Vaccination (on Day 1) and 1 Month After Vaccination
Reported as:
Geometric mean · Fold rise
SSA: GMFR of NTs for RSV A and RSV B From Before Vaccination to 1 Month After Vaccination
Fold riseSSA: RSVpreFSSA: Placebo
RSV A17.5 (15.88 to 19.21)1.0 (0.90 to 1.00)
RSV B18.5 (16.76 to 20.43)1.0 (0.91 to 1.01)

Adverse events

Collected over SSA- LR/SE: Within 7Days after Vaccination (Vacc on Day1);AEs: Within 1 Month (M) after Vacc (Vacc on Day1), including any events reported up to 6 months; SAEs: Any events reported up to 6 months; SSB- LR/SE: Within 7 Days after Vacc1 (Day1 of SSB) Within 7 Days after Vacc 2 (second dose on 1M post-vacc.1); AEs: From Vacc 1 (on Day1) through 1M after Vacc 2 (1M after Vacc1) [approximately up to maximum of 2M], including any events reported up to 7 months; SAEs: any events reported up to 7 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SSA: RSVpreF1/453 (0.2%)5/453 (1.1%)301/453 (66.4%)
SSA: Placebo0/225 (0%)7/225 (3.1%)135/225 (60%)
SSB: RSVpreF, >= 18 to < 60 Years0/96 (0%)7/96 (7.3%)73/96 (76%)
SSB: RSVpreF, >= 60 Years0/107 (0%)15/107 (14%)92/107 (86%)
Most frequent serious events
Showing 10 of 49
Most frequent serious events
EventSSA: RSVpreFSSA: PlaceboSSB: RSVpreF, >= 18 to < 60 YearsSSB: RSVpreF, >= 60 Years
Chest painGeneral disorders0/4530/2251/960/107
Kidney transplant rejectionImmune system disorders0/4530/2251/960/107
COVID-19Infections and infestations0/4530/2251/960/107
CystitisInfections and infestations0/4530/2251/960/107
PneumoniaInfections and infestations0/4530/2251/960/107
UrosepsisInfections and infestations0/4530/2251/960/107
Subdural haematomaInjury, poisoning and procedural complications0/4530/2251/960/107
HypervolaemiaMetabolism and nutrition disorders0/4530/2251/960/107
Deep vein thrombosisVascular disorders0/4530/2251/961/107
HaematomaVascular disorders0/4530/2251/960/107
Most frequent other events
Showing 10 of 119
Most frequent other events
EventSSA: RSVpreFSSA: PlaceboSSB: RSVpreF, >= 18 to < 60 YearsSSB: RSVpreF, >= 60 Years
Fatigue (FATIGUE)General disorders168/45386/22552/9662/107
Injection site pain (PAIN AT INJECTION SITE)General disorders159/45324/22554/9641/107
Headache (HEADACHE)Nervous system disorders128/45368/22542/9638/107
Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders110/45336/22532/9633/107
Diarrhoea (DIARRHEA)Gastrointestinal disorders67/45338/22528/9627/107
Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders56/45323/22521/9627/107
Nausea (NAUSEA)Gastrointestinal disorders53/45323/22515/9613/107
Swelling (SWELLING)General disorders32/4532/2259/9612/107
Erythema (REDNESS)Skin and subcutaneous tissue disorders27/4531/2257/968/107
Vomiting (VOMITING)Gastrointestinal disorders9/4533/2255/962/107

Baseline characteristics

Safety population included all enrolled participants who received the study intervention.

Age, Customized
Age, Customized(Participants)SSA: RSVpreFSSA: PlaceboSSB: RSVpreF, >= 18 to < 60 YearsSSB: RSVpreF, >= 60 YearsTotal
18 to <60 years453225960774
>=60 years000107107
Sex: Female, Male
Sex: Female, Male(Participants)SSA: RSVpreFSSA: PlaceboSSB: RSVpreF, >= 18 to < 60 YearsSSB: RSVpreF, >= 60 YearsTotal
Female2601525653521
Male193734054360
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SSA: RSVpreFSSA: PlaceboSSB: RSVpreF, >= 18 to < 60 YearsSSB: RSVpreF, >= 60 YearsTotal
Hispanic or Latino1024883161
Not Hispanic or Latino34817588101712
Unknown or Not Reported32038
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SSA: RSVpreFSSA: PlaceboSSB: RSVpreF, >= 18 to < 60 YearsSSB: RSVpreF, >= 60 YearsTotal
American Indian or Alaska Native10135
Asian2496241
Native Hawaiian or Other Pacific Islander21104
Black or African American106572515203
White3121526387614
More than one race31004
Unknown or Not Reported550010
08

Study locations

36 sites
  • North Alabama Research Center
    Athens, Alabama 35611, United States
  • Central Research Associates
    Birmingham, Alabama 35205, United States
  • Medical Affiliated Research Center
    Huntsville, Alabama 35801, United States
  • Hope Research Institute
    Phoenix, Arizona 85018, United States
  • The Pain Center of Arizona
    Phoenix, Arizona 85018, United States
  • Hope Research Institute
    Tempe, Arizona 85284, United States
  • Orange County Research Center
    Lake Forest, California 92630, United States
  • Kaiser Permanente
    Los Angeles, California 90027, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • New England Research Associates, LLC
    Bridgeport, Connecticut 06606, United States
  • GW Medical Faculty Associates
    Washington D.C., District of Columbia 20037, United States
  • GW Vaccine Research Unit
    Washington D.C., District of Columbia 20037, United States
  • Alliance for Multispecialty Research, LLC
    Coral Gables, Florida 33134, United States
  • Proactive Clinical Research,LLC
    Fort Lauderdale, Florida 33308, United States
  • Clinical Neuroscience Solutions - Orlando - South Delaney Avenue
    Orlando, Florida 32806, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Alliance for Multispecialty Research, LLC
    Wichita, Kansas 67207, United States
  • Institute of Human Virology (IHV)
    Baltimore, Maryland 21201, United States
  • Jadestone Clinical Research
    Silver Spring, Maryland 20904, United States
  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO
    Springfield, Missouri 65802, United States
  • Bio-Kinetic Clinical Applications LLC dba QPS-MO (Patient Screening Only)
    Springfield, Missouri 65807, United States
  • Bozeman Health Deaconess Hospital
    Bozeman, Montana 59715, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68105, United States
  • University Of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • NYU Langone Health
    New York, New York 10016, United States
  • Columbia University Irving Medical Center
    New York, New York 10032, United States
  • Rochester Clinical Research, LLC
    Rochester, New York 14609, United States
  • Accellacare - Wilmington
    Wilmington, North Carolina 28401, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Alliance for Multispecialty Research, LLC
    Knoxville, Tennessee 37909, United States
  • Orion Clinical Research
    Austin, Texas 78759, United States
  • AIM Trials, LLC
    Plano, Texas 75093, United States
  • Epic Medical Research
    Red Oak, Texas 75154, United States
  • Clinical Trials of Texas, LLC
    San Antonio, Texas 78229, United States
  • Charlottesville Medical Research
    Charlottesville, Virginia 22911, United States
  • Alliance for Multispecialty Research, LLC
    Norfolk, Virginia 23502, United States
09

References and documents

Publications

  • Almeida NC, Parameswaran L, DeHaan EN, Wyper H, Rahman F, Jiang Q, Li W, Patton M, Lino MM, Majid-Mahomed Z, Malkin E, Davis M, Towner WJ, Saharia K, Ilangovan K, Kalinina E, Cooper D, Swanson KA, Anderson AS, Gurtman A, Munjal I. Immunogenicity and Safety of the Bivalent Respiratory Syncytial Virus Prefusion F Subunit Vaccine in Immunocompromised or Renally Impaired Adults. Vaccines (Basel). 2025 Mar 19;13(3):328. doi: 10.3390/vaccines13030328. PubMed 40266222 ↗
  • Davis M, Towner W, DeHaan E, Jiang Q, Li W, Rahman F, Patton M, Wyper H, Lino MM, Sarwar UN, Majid-Mahomed Z, Mehta S, Howitt W, Cannon K, Kalinina E, Cooper D, Swanson KA, Anderson AS, Gurtman A, Munjal I; MONeT Study Team. Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk Conditions. Clin Infect Dis. 2025 Apr 30;80(4):911-920. doi: 10.1093/cid/ciae550. PubMed 39523547 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Mar 2024, 10 months.

Results were first posted in Aug 2025, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2023
First posted
May 6, 2023
StartActual
May 11, 2023
Primary completionActual
Mar 18, 2024
CompletionActual
Mar 18, 2024
Results first posted
Aug 8, 2025
Last update
Aug 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05842967
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 6, 2023
Start date
May 11, 2023
Primary completion
Mar 18, 2024
Completion
Mar 18, 2024
Results posted
Aug 8, 2025
Last update
Aug 8, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abrysvo

Start the discussion